This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Nature Reviews Disease Primers | |
|---|---|
| Title | Nature Reviews Disease Primers |
| Discipline | Medicine |
| Abbreviation | Nat. Rev. Dis. Primers |
| Publisher | Springer Nature |
| Country | United Kingdom |
| History | 2015–present |
| Frequency | Annual/online |
Nature Reviews Disease Primers is a peer-reviewed medical review journal published by Springer Nature that aims to provide comprehensive, authoritative primers on major human diseases and disorders. The journal synthesizes evidence for clinicians and researchers, drawing on contributions from experts affiliated with institutions such as Harvard University, Oxford University, Stanford University, Johns Hopkins University, and University of Cambridge. It positions itself among high-impact titles alongside The Lancet, New England Journal of Medicine, and BMJ.
The journal publishes long-form, state-of-the-art reviews covering pathophysiology, epidemiology, diagnosis, and management, attracting authors from Mayo Clinic, Karolinska Institutet, University of Toronto, Imperial College London, and UCLA Health. Its audience spans clinicians, investigators, and policy stakeholders linked to organizations such as the World Health Organization, Centers for Disease Control and Prevention, National Institutes of Health, European Medicines Agency, and Wellcome Trust. Editorial leadership has connections to editorial boards of Nature Medicine, Nature Reviews Drug Discovery, Science Translational Medicine, Cell, and The BMJ.
Launched in 2015 under the umbrella of Nature Publishing Group, the title emerged during a period of expansion in review publishing that included launches and redesigns by Elsevier, Wolters Kluwer, Taylor & Francis, BMC (BioMed Central), and Frontiers. Early strategic milestones involved collaborations with academic centers such as University College London, McGill University, Peter MacCallum Cancer Centre, Fred Hutchinson Cancer Research Center, and Max Planck Society. Editorial initiatives paralleled trends set by landmark reports from Institute of Medicine, National Academies of Sciences, Engineering, and Medicine, and policy statements from European Commission and G7 health fora.
The journal uses an editor-in-chief and associate editor model with advisory input from editorial boards drawn from institutions like Columbia University, Yale University, Peking University, Seoul National University Hospital, and Monash University. Peer review integrates external reviewers affiliated with Dana-Farber Cancer Institute, Scripps Research Institute, Broad Institute, Ragon Institute, and Rothschild Hospital networks. Article commissioning and curation resemble practices at Nature, Science, Cell Press, The Lancet Oncology, and Nature Communications. Funding and conflict-of-interest policies align with guidelines from bodies such as International Committee of Medical Journal Editors and Committee on Publication Ethics.
Primers address a wide spectrum of conditions including cardiovascular disease topics researched at Cleveland Clinic, Mount Sinai Hospital, St Bartholomew's Hospital, and Karolinska University Hospital; oncological reviews involving contributions from MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Gustave Roussy, and Dana-Farber; infectious disease primers referencing work at Pasteur Institute, London School of Hygiene & Tropical Medicine, Institut Pasteur de Dakar, and National Institute for Communicable Diseases. Neurology pieces draw on teams at Mayo Clinic Hospital, Massachusetts General Hospital, Johns Hopkins Hospital, and Royal Melbourne Hospital. Topics often intersect with translational research centers such as Cold Spring Harbor Laboratory, Salk Institute, Riken, EMBL, and Wellcome Sanger Institute.
The journal has been cited by reviews and guidelines produced by American Heart Association, European Society of Cardiology, American Society of Clinical Oncology, Infectious Diseases Society of America, and World Health Organization technical groups. Its primers inform clinical pathways used in hospitals like Guy's and St Thomas' NHS Foundation Trust, Royal Free Hospital, Singapore General Hospital, and Cleveland Clinic Foundation. Bibliometric attention places it among influential review venues along with Annual Review of Medicine, Nature Reviews Drug Discovery, and Trends in Molecular Medicine. Scholarly reception includes citation in reports from GAVI, UNICEF, Bill & Melinda Gates Foundation, and Global Fund.
Published by Springer Nature, the journal offers a hybrid open-access model mirroring practices at Nature Communications and Scientific Reports, with options for authors from institutions supported by agreements with consortia such as CERN, Karolinska Institutet Library, Jisc, Big Ten Academic Alliance, and national deals in Germany, France, and United Kingdom. Licensing choices reference Creative Commons frameworks used by Public Library of Science, eLife, and BioMed Central. Subscription access is available through university libraries at Harvard Library, Bodleian Libraries, Library of Congress, and Bibliothèque nationale de France.
Notable primers have covered diseases like Alzheimer's disease with contributors from Alzheimer's Association, Parkinson's disease with links to Michael J. Fox Foundation, chronic obstructive pulmonary disease reflecting work at American Thoracic Society, and cancer immunotherapy aligning with breakthroughs from James P. Allison and Tasuku Honjo-related research centers. Influential articles have been cited by clinical guideline committees at National Institute for Health and Care Excellence, U.S. Preventive Services Task Force, European Centre for Disease Prevention and Control, and incorporated into curricula at Stanford School of Medicine, Yale School of Medicine, University of Oxford Medical School, and Imperial College School of Medicine.
Category:Medical journals